Test Compendium is your definitive resource for detailed information on a wide array of diagnostic tests. Each entry in our compendium is meticulously cataloged to aid healthcare providers in selecting and interpreting the right tests for their patients.
Displaying 226 - 250 of 475
Concurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline) Methodology Molecular Test Description Disease Solid tumors; Breast cancer, Ovarian cancer,
Concurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue Methodology Molecular Test Description Disease Solid tumorsOn Tissue: siPortfolio Multi-Omics™ • NGS (500+ genes, TMB, MSI)
LymphoSight™ Test Description Probes/Genes IHC/CISH ALK1, BCL-1, BCL-2, BCL-6, BRAF, Bob1, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20, CD21, CD23, CD25*, CD30, CD43, CD79a, CD138, C-MYC, EBV-LMP, Granzyme B, ICOS*, IgA, IgG, IgG4, IgM, Kappa, Ki-67, Lambda, LEF1*, Mum1, OCT2, Pax5, Perforin, PD-1, TIA1. *: Pending CISH: EBER, Kappa,
PRPF8 single gene test Methodology Molecular Test Description Genes PRPF8 Disease Lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, bladder urothelial carcinoma, high
PTEN Single Gene Test Methodology Molecular Test Description Genes PTEN (exons 5-6, 9) Disease Glioma, melanoma, prostate, endometrial, breast, ovarian, renal, colon, lung cancers, inherited hamartoma
PTPN11 single gene test Methodology Molecular Test Description Genes PTPN11 Disease Juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, myelodysplastic neoplasm, nonsyndromic acute myeloid
PTPN6 Methodology Molecular Test Description Genes PTPN6 (exons 11-12) Disease Polycythemia, intestinal cancer, peritoneal cancer, skin cancer, and lung adenocarcinomaDeep next generation sequencing of
RAF1 single gene test Methodology Molecular Test Description Genes RAF1 Disease Colon adenocarcinoma, lung adenocarcinoma, bladder urothelial carcinoma, endometrial endometrioid adenocarcinoma, and cutaneous
RB1 single gene test Methodology Molecular Test Description Genes RB1 Disease childhood cancer retinoblastoma (RB), bladder cancer, osteogenic sarcoma, lung adenocarcinoma, small cell lung carcinoma, breast
RBM15 single gene test Methodology Molecular Test Description Genes RBM15 Disease Megakaryoblastic Acute Myeloid Leukemia With T(1;22)(P13;Q13) and Acute Megakaryocytic Leukemia, breast invasive ductal
RET single gene test Methodology Molecular Test Description Genes RET Disease Lung adenocarcinoma, colon adenocarcinoma, thyroid gland medullary carcinoma, cutaneous melanoma, and melanomaMolecular test
ROS1 single gene test Methodology Molecular Test Description Genes ROS1 Disease Lung adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, colon adenocarcinoma, and melanomaMolecular test
RUNX1 (runt related transcription factor 1) Methodology Molecular Test Description Genes RUNX1 Disease Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), familial platelet disorder with
SETBP1 single gene test Methodology Molecular Test Description Genes SETBP1 Disease Juvenile myelomonocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic neoplasm, lung adenocarcinoma,
SF3B1 Mutation Analysis Methodology Molecular Test Description Genes SF3B1 (exons 13-19) Disease Myelodysplastic neoplasm, sideroblastic anemia, chronic lymphocytic leukemia (CLL), Acute myeloid leukemia
SH2B3 Single Gene test Methodology Molecular Test Description Genes SH2B3 Disease Familial erythrocytosis, thrombocythemia, acute lymphoblastic leukemia (ALL), autoimmune disorders, colon adenocarcinoma,
SMO single gene test Methodology Molecular Test Description Genes SMO Disease Lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and cutaneous
SRSF2 Mutation Analysis Methodology Molecular Test Description Genes SRSF2 Disease Myelodysplastic neoplasm (MDS), chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), chronic myelomonocytic
STAG2 single gene test Methodology Molecular Test Description Genes STAG2 Disease Myelodysplastic neoplasm (MDS), Acute myeloid leukemia (AML), bladder cancer, Mullegama-Klein-Martinez Syndrome and Holoprosencephaly
TCF3 single gene test Methodology Molecular Test Description Genes TCF3 Disease Pre-B-cell acute lymphoblastic leukemia (t(1;19), with PBX1), Childhood leukemia (t(19;19), with TFPT) and Acute leukemia
TCRB gene rearrangement Alternative Name T-Cell Beta Gene Rearrangement, T-Cell Clonality Assessment Methodology Molecular Test Description Genes TCRB Disease T-cell neoplasmT-cell Receptor (TCR) Beta
TCRG Gene rearrangement Alternative Name T-Cell Gamma Gene Rearrangement Methodology Molecular Test Description Genes TCRG Disease T-cell neoplasmT-cell Clonality Panel (TCRB, TCRG), interrogates both
TCRG Gene rearrangement reflex to TCRG Gene rearrangement Methodology Molecular Test Description Genes TCRG reflex to TCRB Disease T-cell neoplasmT-cell Clonality Panel (TCRB, TCRG), interrogates both
TET2 Mutation Analysis Methodology Molecular Test Description Genes TET2 Disease Myelodysplastic neoplasm (MDS), Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic Myelomonocytic
TP53 Mutation Analysis Methodology Molecular Test Description Genes TP53 (exons 2-11) Disease Li-Fraumeni Syndrome, breast cancer, osteosarcoma, soft tissue sarcoma, some leukemias and lymphomas, papilloma
U2AF1 Single Gene Methodology Molecular Test Description Genes U2AF1 Disease Myelodysplastic neoplasm (MDS), chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), chronic myelomonocytic leukemia
Wilms' Tumor 1 (WT1) Mutation Analysis Methodology Molecular Test Description Genes WT1 Disease Wilms Tumor, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, kidney cancer,
XPO Single Gene Test Methodology Molecular Test Description Genes XPO (exons 12-13,15) Disease Diseases associated with XPO include Influenza and Primary Mediastinal Large B-Cell Lymphoma. lung adenocarcinoma,
With core values rooted in service and integrity, our leadership team sets the bar high.
We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).
We also hold select state licensure where required.